CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual Top Employer survey of the biopharmaceutical and related industries. In its first year of eligibility for the award, Ionis was ranked second based on industry-leading innovation, strong alignment of company and employ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., Ionis' chief executive officer, was awarded the 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (OTS), a nonprofit organization that fosters academia and industry-based research and development of oligonucleotide therapeutics. The OTS Lifetime A...
On October 17, 2025, Capricorn Fund Managers Ltd disclosed a new stake in Ionis Pharmaceuticals, acquiring approximately 162,800 shares in a trade estimated at $10.65 million based on average quarterly pricing.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, October 29th at 11:30 a.m. Eastern Time to discuss its third quarter 2025 financial results and progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Shareholder/Analyst Call October 7, 2025 8:30 AM EDT Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sotirios Tsimikas - Senior Vice President of Global Cardiovascular Development Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Kenneth Newman - Senior Vice President of ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company's recent and near-term independent launches, growing pipeline of wholly owned medicines, innovative technology and clear path to sustained positive cash flow. Additionally, a leading physician will discuss the current t...
Ionis Pharmaceuticals said on Monday its experimental brain disorder drug met the main goal in an early-to-late-stage study.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.